$155 Million is the total value of Birchview Capital, LP's 67 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 75.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AZYO | Buy | AZIYO BIOLOGICS INC | $8,352,000 | +2300.0% | 1,417,923 | +2735.8% | 5.39% | +2172.6% |
| NBIX | Buy | NEUROCRINE BIOSCIENCES INC | $7,597,000 | -1.2% | 89,200 | +11.2% | 4.90% | -6.4% |
| BDSX | Buy | BIODESIX INC | $6,627,000 | -27.0% | 1,252,753 | +13.4% | 4.27% | -30.9% |
| INBX | New | INHIBRX INC | $1,747,000 | – | 40,000 | +100.0% | 1.13% | – |
| BHVN | Buy | BIOHAVEN PHARMACEUTICAL HOLDING CO LTD | $1,654,000 | +19.1% | 12,000 | +20.0% | 1.07% | +12.9% |
| NKTR | Buy | NEKTAR THERAPEUTICS | $1,351,000 | +4.5% | 100,000 | +38.9% | 0.87% | -1.0% |
| GOSS | Buy | GOSSAMER BIO INC | $1,131,000 | +124.9% | 100,000 | +150.0% | 0.73% | +113.2% |
| New | 2SEVENTY BIO INC | $718,000 | – | 27,999 | +100.0% | 0.46% | – | |
| AVEO | Buy | AVEO PHARMACEUTICALS INC | $657,000 | +166.0% | 140,000 | +250.0% | 0.42% | +152.4% |
| New | VENTYX BIOSCIENCES INC | $497,000 | – | 25,000 | +100.0% | 0.32% | – | |
| SILK | New | SILK ROAD MEDICAL INC | $341,000 | – | 8,000 | +100.0% | 0.22% | – |
| PFE | New | PFIZER INC | $236,000 | – | 4,000 | +100.0% | 0.15% | – |
| LSF | Buy | LAIRD SUPERFOOD INC | $235,000 | -12.0% | 18,000 | +28.6% | 0.15% | -16.5% |
| New | DOCGO INC | $94,000 | – | 10,000 | +100.0% | 0.06% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACCELERATE DIAGNOSTICS INC | 36 | Q3 2023 | 34.6% |
| QUIDELORTHO CORP | 36 | Q3 2023 | 8.6% |
| MASIMO CORP | 36 | Q3 2023 | 2.2% |
| PIONEER NATURAL RESOURCES CO (PXD) | 36 | Q3 2023 | 0.7% |
| XENCOR INC | 35 | Q3 2023 | 0.4% |
| NEUROCRINE BIOSCIENCES INC | 33 | Q3 2023 | 7.4% |
| CORCEPT THERAPEUTICS INC | 32 | Q3 2023 | 1.2% |
| BIOGEN INC | 31 | Q2 2022 | 3.1% |
| CONTRAFECT CORP | 30 | Q3 2022 | 1.6% |
| YIELD10 BIOSCIENCE INC | 26 | Q3 2023 | 0.6% |
View Birchview Capital, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SOLENO THERAPEUTICS INC | March 19, 2019 | 742,635 | 2.3% |
| YIELD10 BIOSCIENCE, INC. | December 29, 2017 | 186,079 | 2.2% |
| HANSEN MEDICAL INC | February 16, 2016 | ? | ? |
| METABOLIX, INC. | June 23, 2015 | 749,696 | 2.8% |
View Birchview Capital, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3/A | 2024-02-20 |
| 4/A | 2024-02-20 |
| SC 13G/A | 2024-02-20 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-08 |
| 13F-HR | 2023-05-12 |
| SC 13G/A | 2023-04-07 |
| 4 | 2023-03-27 |
| 3 | 2023-02-13 |
View Birchview Capital, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.